undamentalytics Newsletter
Sign in

Whitehawk Therapeutics, Inc. cash flow statement

In fiscal 2025, Whitehawk Therapeutics, Inc.'s operations generated −$97.4m of cash; it spent $552,000 on capital projects, leaving free cash flow of −$98.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−6−24−13−22−50−60−60−97−69
Depreciation and amortisation000000000
Stock-based pay3102101211109
Capital spending000004210
Free cash flow−6−24−13−22−50−64−61−98−69
Free cash flow after stock pay−9−25−13−25−60−76−72−108−78
Dividends paid———40————
Shares issued52—101550————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Whitehawk Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Whitehawk Therapeutics, Inc.